Child-Onset SLE Affects Organs in the Long Term

BY BRUCE JANCIN

Denver Bureau

VIENNA — Nearly two-thirds of a cohort of childhood-onset systemic lupus erythematosus patients had evidence of irreversible organ damage after a decade of disease, Vibke Lilleby, M.D., said at the annual European congress of rheumatology.

The most frequently affected organ systems were the neuropsychiatric, in 28% of cases; renal, in 13%; and musculoskeletal, in 13%, according to Dr. Lilleby of the University of Oslo.

Her 71-patient series with childhoodonset SLE had a mean age of 12.5 years at lupus symptom onset and a 10.8-year disease duration. Their mean Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage

Major Infections Rife in Patients Who Have SLE

VIENNA — Patients with systemic lupus erythematosus experience an exceptionally high rate of major infections, Irene E.M. Bultink, M.D., reported at the annual European congress of rheumatology.

In her retrospective series of 103 unselected SLE patients, one-half experienced a collective total of 115 infections—not including lower urinary tract infections—during their mean 7-year disease duration.

Of these infections, 37% were classified as major in that they required hospitalization and intravenous antibiotics. The most common sites of major infections were the lower respiratory tract (33%), systemic infections (19%), and the gastrointestinal tract (12%), said Dr. Bultink, a rheumatologist at Slotervaart Hospital, Amsterdam.

Staphylococcus aureus was identified as the causal organism in 16% of major infections, making it the No. 1 culprit microorganism in severe episodes.

In a multivariate regression analysis, the significant independent risk factors for development of major infections were the presence of IgG anticardiolipin antibodies; leukopenia during the disease course; use of methotrexate at any time in treating SLE; and longer disease duration.

Turning to the 115 infections in the group as a whole, microorganisms were isolated in 50% of cases. The single most common type of infection was herpes zoster skin eruption at 16% of all infections.

Of infections in the SLE patients, 29% involved the skin and/or mucosa, 22% involved the lower respiratory tract, and 14% involved the upper respiratory tract, she said at the meeting sponsored by the European League Against Rheumatism.

Five patients developed opportunistic infections. There were two cases of *Candida albicans* esophagitis; one of sepsis from cytomegalovirus and *C. albicans*; one case of sinusitis caused by *Aspergillus fumigatus*; and a *Klebsiella pneumoniae* pneumonia.

-Bruce Jancin

Index (SDI)—a validated measure of non-reversible organ damage—was 1.3.

The independent predictors of a higher SDI were ever having taken cyclophosphamide, hypertension, and disease duration. In contrast, cumulative corticosteroid dose, the presence of renal disease at diagnosis, and erythrocyte sedimentation rate at diagnosis were among the examined factors that did not predict subsequent organ damage.


The high rate of irreversible organ dam-

age in this cohort is a byproduct of the greatly improved long-term prognosis for childhood-onset SLE during the past 4 decades. Patients who in former years would have had a poor life expectancy are surviving much longer, with an associated increase in multiorgan morbidity due to the disease process itself or to its treatment, she explained at the congress, sponsored by the European League Against Rheumatism.

In a separate comparative study involving 70 of the same Norwegian patients

with childhood-onset SLE and an equal number of matched controls, Dr. Lilleby found that osteopenia was much more frequent in the childhood-onset SLE group. For example, 41% of them had osteopenia at the lumbar spine and 40% at the femoral neck vs. 7% and 6% of the controls.

Cumulative dose of corticosteroids was a strong predictor of reduced bone mass at these sites. Reduced bone mineral density at the lumbar spine was also associated with male gender.



© 2005 Bristol-Myers Squibb Company V5-K0066F 5/05 Printed in USA